Abstract:Haoqian Chen, 1 Xiao Zheng, 2, 3 Lingjue Li, 1 Lishuxin Huang, 1 Weiwei Huang, 2 Yanbing Ma 2 1 Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, People's Republic of China; 2 Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China; 3 School of Life Sciences, Yunnan University, Kunming, People's Republic of China Correspondence: Lishuxin Huang, Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, 650504, People's Republic of China, Tel/Fax +86 871 6592 6040, Email Yanbing Ma, Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 935 Jiaoling Road, Kunming, 650032, People's Republic of China, Tel +86 871 6833 9287, Fax +86 871 6833 4483, Email Background: Peptide-based vaccines have broad application prospects because of their safety, simple preparation, and effectiveness, especially in the development of personalized cancer vaccines, which have shown great advantages. However, the current peptide-based vaccines often require artificial synthesis and intricate delivery technology, which increases the cost and complexity of preparation. Methods: Here, we developed a simple technique for combining a peptide and a delivery system using the natural secretion system of bacteria. Specifically, we biosynthesized an antigenic peptide in bacteria, which was then extracellularly released through the bacterial secretory vesicles, thus simultaneously achieving the biosynthesis and delivery of the peptide. Results: The system utilizes the natural properties of bacterial vesicles to promote antigen uptake and dendritic cell (DC) maturation. Therefore, tumor-specific CD4 + Th1 and CD8 + cytotoxic T lymphocyte (CTL) responses were induced in TC-1 tumor-bearing mice, thereby efficiently suppressing tumor growth. Conclusion: This research promotes innovation and extends the application of peptide-based vaccine biosynthesis technology. Importantly, it provides a new method for personalized cancer immunotherapy that uses screened peptides as antigens in the future. Keywords: tumor immunization, peptide vaccine, outer membrane vesicle, delivery system Immunotherapy is considered a potential cancer treatment strategy, 1 in which therapeutic cancer vaccines are an important factor. 2 The effectiveness of therapeutic cancer vaccines has been demonstrated in a variety of cancer types. At present, the therapeutic cancer vaccine strategy targeting screened personalized neoantigens has gradually shown great application prospects. 3 Enabling the simultaneous display of multiple tumor antigens by linking antigens using a plug-and-play system may be a valuable approach for the development of personalized tumor vaccines against complex and heterogeneous tumor antigens. 4,5 Recently, peptide-based vaccines have received increasing attention in both infectious disease and cancer research fields because of their convenient preparation, high safety, and favorable immunogenicity. Peptide-based vaccines can be intelligently designed to target specific MHC molecules for efficient presentation, thereby enhancing B-cell and T-cell responses. An advantage of peptide-based vaccines is that they are easy to synthesize, eliminating the need for many tedious processes, such as the expression and purification of vaccine antigens and in vitro transcription of nucleic acid vaccines. Peptide-based vaccines can be easily obtained through artificial synthesis, and have high purity. However, although artificially synthesized peptides are convenient, they have a higher cost. In addition, peptide-based vaccines generally require a suitable delivery system to protect and deliver the peptide, which increases the cost and complexity of peptide-based vaccine preparation. Currently, more than 500,000 women are diagnosed with cervical cancer each year, and the disease causes more than 300,000 deaths worldwide. In most cases, high-risk subtypes of human papilloma virus (HPV) are the cause of the disease. However the disease is largely preventable. 6 We have also conducted some previous research on the treatment of this disease and we established a vaccine technology platform based on norovirus virus-like particles (VLPs) displaying personalized antigens. 7 -Abstract Truncated-

Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles

Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances

The Role and Development of Peptide Vaccines in Cervical Cancer Treatment

Precisely Shaped Self-Adjuvanting Peptide Vaccines with Enhanced Immune Responses for HPV-Associated Cancer Therapy.

Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review

Peptide Vaccination – a Novel Therapeutically Option for Cancer Patients

Vaccination with Synthetic Long Peptide Formulated with CpG in an Oil-in-water Emulsion Induces Robust E7-specific CD8 T Cell Responses and TC-1 Tumor Eradication

Clinical Application of Peptide Vaccine for Cancer

Vaccination with the Repeat Β-Hcg C-terminal Peptide Carried by Heat Shock Protein-65 (HSP65) for Inducing Antitumor Effects

Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy

Analysis of the development prospects of cancer therapeutic vaccines based on the current research status of peptide vaccines

Peptide-based vaccine for cancer therapies

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

Cancer Immunoinformatics: A Promising Era in the Development of Peptide Vaccines for Human Papillomavirus-induced Cervical Cancer

Insights into peptide-based vaccine design for cancer immunotherapy

Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity

Co-assembled and Self-Delivered Epitope/cpg Nanocomplex Vaccine Augments Peptide Immunogenicity for Cancer Immunotherapy

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects